MX2023001059A - Modulacion de la respuesta inmunitaria mediada por la aminopeptidasa 2 del reticulo endoplasmico (erap2). - Google Patents

Modulacion de la respuesta inmunitaria mediada por la aminopeptidasa 2 del reticulo endoplasmico (erap2).

Info

Publication number
MX2023001059A
MX2023001059A MX2023001059A MX2023001059A MX2023001059A MX 2023001059 A MX2023001059 A MX 2023001059A MX 2023001059 A MX2023001059 A MX 2023001059A MX 2023001059 A MX2023001059 A MX 2023001059A MX 2023001059 A MX2023001059 A MX 2023001059A
Authority
MX
Mexico
Prior art keywords
endoplasmic reticulum
erap2
modulation
immune response
mediated immune
Prior art date
Application number
MX2023001059A
Other languages
English (en)
Spanish (es)
Inventor
Carmelo Romano
Sahar Gelfman
Aris Baras
Giovanni Coppola
Manuel Allen Revez Ferreira
Ann Ligocki
Arden Moscati
Eli A Stahl
Jack A Kosmicki
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2023001059A publication Critical patent/MX2023001059A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8103—Exopeptidase (E.C. 3.4.11-19) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/11—Aminopeptidases (3.4.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Analytical Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Mycology (AREA)
MX2023001059A 2020-07-25 2021-07-23 Modulacion de la respuesta inmunitaria mediada por la aminopeptidasa 2 del reticulo endoplasmico (erap2). MX2023001059A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063056562P 2020-07-25 2020-07-25
US202163171672P 2021-04-07 2021-04-07
PCT/US2021/043062 WO2022026336A1 (en) 2020-07-25 2021-07-23 Modulation of endoplasmic reticulum aminopeptidase 2 (erap2)-mediated immune response

Publications (1)

Publication Number Publication Date
MX2023001059A true MX2023001059A (es) 2023-04-26

Family

ID=77564145

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001059A MX2023001059A (es) 2020-07-25 2021-07-23 Modulacion de la respuesta inmunitaria mediada por la aminopeptidasa 2 del reticulo endoplasmico (erap2).

Country Status (10)

Country Link
US (1) US12662539B2 (cg-RX-API-DMAC7.html)
EP (1) EP4188963A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023536437A (cg-RX-API-DMAC7.html)
KR (1) KR20230043888A (cg-RX-API-DMAC7.html)
CN (1) CN116194484A (cg-RX-API-DMAC7.html)
AU (1) AU2021316196B2 (cg-RX-API-DMAC7.html)
CA (1) CA3189755A1 (cg-RX-API-DMAC7.html)
IL (1) IL299986A (cg-RX-API-DMAC7.html)
MX (1) MX2023001059A (cg-RX-API-DMAC7.html)
WO (1) WO2022026336A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3189755A1 (en) 2020-07-25 2022-02-03 Regeneron Pharmaceuticals, Inc. Modulation of endoplasmic reticulum aminopeptidase 2 (erap2)-mediated immune response
WO2023064850A1 (en) * 2021-10-14 2023-04-20 Regeneron Pharmaceuticals, Inc. Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (erap1) inhibitors
US12613286B2 (en) 2024-01-22 2026-04-28 Garrett Transportation I Inc. System and method for battery parameter recharacterization
US12704384B2 (en) 2024-05-28 2026-08-11 Garrett Transportation 1 Inc. Range estimation for battery electric vehicles
CN118593462B (zh) * 2024-06-28 2026-01-27 沈阳药科大学 鼠尾草酸作为erap1的抑制剂在制备治疗强直性脊柱炎药物中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7005269B2 (en) 2002-06-06 2006-02-28 The Regents Of The University Of California ERAAP modulators regulate immune responses
WO2012009547A2 (en) 2010-07-14 2012-01-19 The Regents Of The University Of California Biomarkers for diagnosis of transient ischemic attacks
WO2012047294A2 (en) 2010-10-06 2012-04-12 Ludwig Institute For Cancer Research Ltd Antibodies directed against hla-b27 homodimers and methods and uses thereof in diagnosis and therapy
US8969254B2 (en) 2010-12-16 2015-03-03 Dana-Farber Cancer Institute, Inc. Oligonucleotide array for tissue typing
TWI619729B (zh) 2012-04-02 2018-04-01 再生元醫藥公司 抗-hla-b*27抗體及其用途
ES2762403T3 (es) 2012-04-26 2020-05-25 Stichting Vumc Biomarcadores
WO2014058976A2 (en) 2012-10-10 2014-04-17 Teva Pharmaceutical Industries Ltd. Biomarkers predictive for clinical response for glatiramer acetate
KR101748867B1 (ko) 2013-04-19 2017-06-20 주식회사 젠큐릭스 조기 유방암 예후 예측 진단용 자동화 시스템
EP3489369B1 (en) 2013-06-25 2020-10-28 Turun yliopisto Method of predicting risk for type 1 diabetes
US9907833B2 (en) 2013-07-25 2018-03-06 University Of Florida Research Foundation, Incorporated Use of relaxin to treat placental syndromes
US10927412B2 (en) 2013-10-01 2021-02-23 The Regents Of The University Of California Endometriosis classifier
US10166210B2 (en) 2014-06-12 2019-01-01 Nsabp Foundation, Inc. Methods of subtyping CRC and their association with treatment of colon cancer patients with oxaliplatin
HK1257443A1 (zh) 2015-08-21 2019-10-18 The Children's Hospital Of Philadelphia 治疗具有dcr3或dcr3网络基因中的遗传变异的患者的自身免疫病症的方法
WO2017191274A2 (en) 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
GB201609712D0 (en) 2016-06-03 2016-07-20 Babraham Inst Disease targets and biomarkers
US20190375842A1 (en) 2018-01-04 2019-12-12 Vanderbilt University Check point inhibition in organ fibrosis
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
US11632728B2 (en) 2019-07-18 2023-04-18 Qualcomm Incorporated Directional measurements for sidelink synchronization signal transmission
US12195723B2 (en) 2019-11-08 2025-01-14 The Broad Institute, Inc. Engineered antigen presenting cells and uses thereof
WO2021113805A1 (en) 2019-12-05 2021-06-10 The General Hospital Corporation Multi-biomarker prediction models for multiple infection episodes following blunt trauma
CA3189755A1 (en) 2020-07-25 2022-02-03 Regeneron Pharmaceuticals, Inc. Modulation of endoplasmic reticulum aminopeptidase 2 (erap2)-mediated immune response

Also Published As

Publication number Publication date
US12662539B2 (en) 2026-06-23
EP4188963A1 (en) 2023-06-07
JP2023536437A (ja) 2023-08-25
WO2022026336A1 (en) 2022-02-03
CN116194484A (zh) 2023-05-30
CA3189755A1 (en) 2022-02-03
KR20230043888A (ko) 2023-03-31
IL299986A (en) 2023-03-01
AU2021316196B2 (en) 2025-09-25
US20230059929A1 (en) 2023-02-23
AU2021316196A1 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
NI202100009A (es) Métodos para reducir la necesidad de revascu
CO2019006292A2 (es) Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares
BR112022007595A2 (pt) Métodos para tratar doença de alzheimer
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
MX2019010994A (es) Metodos para tratar enfermedades y trastornos mediados por el complemento.
AR116753A1 (es) Proceso de preparación de un derivado de pirazolsulfonilamida
CO2022017072A2 (es) Imidazopiridazinas como moduladores de il-17
MX2020001732A (es) Tratamiento de las afecciones del sistema nervioso central.
MX2024006689A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
MX2021006951A (es) Formas cristalinas y formas de sal de un inhibidor de cinasa.
CL2022003511A1 (es) Inhibidores de alk2 para el tratamiento de la anemia.
MX2022006176A (es) Terapia combinada que comprende un inhibidor de alk2 y un inhibidor de jak2.
MX2018015022A (es) Métodos para el tratamiento de la enfermedad de alzheimer.
MX2022013233A (es) Metodo de seleccion de pacientes para tratamiento con una combinacion de un inhibidor de axl y un modulador de punto de control inmunitario.
MX2023000763A (es) Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrofilas.
MX387658B (es) Métodos para tratar y/o prevenir queratosis actínica.
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
AR114306A1 (es) Tratamiento y prevención de trastornos del sueño
MX2021009488A (es) Uso de vibegron para tratar la vejiga hiperactiva.
MX2023011720A (es) Una composicion para su uso en el tratamiento de mhc-i-opatias.
MX2021006915A (es) Inhibidores de cxcr7 para el tratamiento de cancer.
CL2019002704A1 (es) Nuevos métodos para el tratamiento de la esclerosis múltiple.
MX2021009326A (es) Pridopidina de dosis baja para mal de parkinson y otras enfermedades asociadas con parkinsonismo.
CO2023014650A2 (es) Dosificación y administración de l-asparaginasa recombinante